journal
https://read.qxmd.com/read/38734999/ten-year-durability-hemodynamic-performance-and-clinical-outcomes-after-transcatheter-aortic-valve-implantation-using-a-self-expanding-device
#1
JOURNAL ARTICLE
Karim Elbasha, Jatinderjit Kaur, Mohammad Abdelghani, Martin Landt, Sultan Alotaibi, Ahmed Abdelaziz, Mohamed Abdel-Wahab, Ralph Toelg, Volker Geist, Gert Richardt, Abdelhakim Allali
INTRODUCTION: The expansion of transcatheter aortic valve implantation (TAVI) to low-risk and younger patients has increased the relevance of the long-term durability of transcatheter heart valves (THV). The present study aims to assess the 10-year durability, hemodynamic performance, and clinical outcomes after TAVI using the CoreValve system. METHODS: An analysis from a prospective registry with predefined clinical and echocardiographic follow-up included 302 patients who underwent TAVI with the CoreValve system between 2007 and 2015...
May 12, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38709436/real-world-clinical-burden-of-newly-diagnosed-heart-failure-in-thai-patients
#2
JOURNAL ARTICLE
Thanita Boonyapiphat, Thidaporn Tangkittikasem, Artit Torpongpun, Vichai Senthong, Panyapat Jiampo
INTRODUCTION: There are limited data on the burden of newly diagnosed patients with heart failure (HF) in Thailand. Thus, this study aimed to fully understand the hospitalization, rehospitalization, mortality rates, demographics and characteristics, and quality of care in these patients. METHOD: A retrospective review of all eligible adult patients' medical records from 2018 and 2019 was conducted at five hospitals. The patients were newly diagnosed with HF, as indicated by the International Classification of Diseases (ICD)-10 code "I50...
May 6, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38703292/broadening-perspectives-of-artificial-intelligence-in-echocardiography
#3
REVIEW
Karthik Seetharam, Harshith Thyagaturu, Gabriel Lora Ferreira, Aditya Patel, Chinmay Patel, Asim Elahi, Roman Pachulski, Jilan Shah, Parvez Mir, Arunita Thodimela, Manya Pala, Zeyar Thet, Yasmin Hamirani
Echocardiography frequently serves as the first-line treatment of diagnostic imaging for several pathological entities in cardiology. Artificial intelligence (AI) has been growing substantially in information technology and various commercial industries. Machine learning (ML), a branch of AI, has been shown to expand the capabilities and potential of echocardiography. ML algorithms expand the field of echocardiography by automated assessment of the ejection fraction and left ventricular function, integrating novel approaches such as speckle tracking or tissue Doppler echocardiography or vector flow mapping, improved phenotyping, distinguishing between cardiac conditions, and incorporating information from mobile health and genomics...
May 4, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38687432/management-of-heart-failure-in-a-resource-limited-setting-expert-opinion-from-india
#4
REVIEW
Peeyush Jain, Santanu Guha, Soumitra Kumar, J P S Sawhney, Kamal Sharma, K P Sureshkumar, Ashwani Mehta, Rajnish Dhediya, Kumar Gaurav, Rajan Mittal, Bhavesh Kotak
Heart failure poses a global health challenge affecting millions of individuals, and access to guideline-directed medical therapy is often limited. This limitation is frequently attributed to factors such as drug availability, slow adoption, clinical inertia, and delayed diagnosis. Despite international recommendations promoting the use of guideline-directed medical therapy for heart failure management, personalized approaches are essential in settings with resource constraints. In India, crucial treatments like angiotensin II receptor blocker neprilysin inhibitors and sodium-glucose co-transporter 2 inhibitors are not fully utilized despite their established safety and efficacy...
April 30, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38664318/derivation-of-stroke-volume-from-pulmonary-artery-pressures
#5
JOURNAL ARTICLE
Ivan H W Yim, Nigel E Drury, Hoong Sern Lim
INTRODUCTION: Intermittent cardiac output (CO) studies using thermodilution are considered the gold standard. We have developed a stroke volume (SV) calculator from pulmonary pulse pressure (PP) to allow continuous monitoring of SV and CO from PP. METHODS: Hemodynamic data on 169 patients following orthotopic heart transplantation were used to compare our calculator-derived SV (and SV index, or SVi) against thermodilution-derived SV on admission into intensive care unit immediately following heart transplantation (T0) and 6 h after admission (T6)...
April 25, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38630393/intravascular-imaging-guided-versus-coronary-angiography-guided-complex-pci-a-meta-analysis-of-randomized-controlled-trials
#6
JOURNAL ARTICLE
Mohamed Hamed, Sheref Mohamed, Mohamed Mahmoud, Jonathan Kahan, Amr Mohsen, Faisal Rahman, Waleed Kayani, Fernando Alfonso, Emmanuel S Brilakis, Islam Y Elgendy, Mamas A Mamas, Ayman Elbadawi
INTRODUCTION: Trials evaluating the role of intravascular imaging in percutaneous coronary intervention (PCI) for complex coronary artery disease have yielded mixed results. This study aimed to compare the outcomes of intravascular imaging specifically intravascular ultrasound (IVUS) with those from conventional coronary angiography in complex PCI. METHODS: Comprehensive electronic search of MEDLINE, EMBASE, and Cochrane databases was performed until March 2023 for randomized clinical trials (RCTs) comparing intravascular imaging with coronary angiography in patients undergoing complex PCI...
April 17, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38615093/tafamidis-61%C3%A2-mg-patient-characteristics-and-persistency-a-retrospective-analysis-of-german-statutory-health-insurance-data-iqvia%C3%A2-lrx
#7
JOURNAL ARTICLE
Sepideh Attal, Jason Kemner, Jose Alvir, Sebastian Barth, Sofia Schuessler
INTRODUCTION: Tafamidis is the first drug approved by the European Commission for the treatment of wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. Real-world treatment patterns of tafamidis 61 mg in Germany are not well studied in patients with ATTR-CM. METHODS: This was a non-interventional, retrospective, observational cohort study of adult patients in Germany based on the IQVIA pharmacy claims database (IQVIA™ LRx)...
April 13, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38536649/emergent-coronary-thrombectomy-for-acute-myocardial-infarction-immediately-following-craniotomy-with-tumor-resection
#8
JOURNAL ARTICLE
Curtis R Ginder, Giselle A Suero-Abreu, Saad S Ghumman, Brian A Bergmark, Omar Arnaout, Robert P Giugliano
The management of perioperative acute myocardial infarction (AMI) following oncologic neurosurgery requires balancing competing risks of myocardial ischemia and postoperative bleeding. There are limited human data to establish the safest timing of antiplatelet or anticoagulation therapy following neurosurgical procedures. For patients with malignancy experiencing AMI in the acute postoperative period, staged percutaneous coronary intervention (PCI) with upfront coronary aspiration thrombectomy followed by delayed completion PCI may offer an opportunity for myocardial salvage while minimizing postoperative bleeding risks...
March 27, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38521883/real-world-effectiveness-of-high-dose-tafamidis-on-neurologic-disease-progression-in-mixed-phenotype-variant-transthyretin-amyloid-cardiomyopathy
#9
JOURNAL ARTICLE
Nicholas Streicher, Leslie Amass, Rong Wang, Jennifer M Stephens, Traci LeMasters, Rutika Raina, Emma Merrill, Farooq H Sheikh
INTRODUCTION: Transthyretin amyloidosis (ATTR) is a progressive, heterogeneous rare disease manifesting as ATTR polyneuropathy (ATTR-PN), ATTR cardiomyopathy (ATTR-CM), or a mixed phenotype. Tafamidis meglumine (20 mg po qd) is approved in some markets to delay neurologic progression in ATTR-PN, while high-dose tafamidis (80/61 mg po qd) is approved worldwide to reduce cardiovascular mortality and cardiovascular-related hospitalization in ATTR-CM. The objective of this study was to assess the real-world benefit of high-dose tafamidis for delaying neurologic progression in patients with mixed-phenotype variant ATTR-CM (ATTRv-CM)...
March 23, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38514522/effects-of-ivabradine-on-myocardial-perfusion-in-chronic-angina-a-prospective-preliminary-open-label-single-arm-study
#10
JOURNAL ARTICLE
Olímpio R França Neto, Miguel M Fernandes-Silva, Rodrigo J Cerci, Carlos A Cunha-Pereira, Margaret Masukawa, João V Vitola
INTRODUCTION: Ivabradine reduces heart rate (HR), episodes of angina, and nitrate consumption, and increases exercise capacity in patients with chronic angina (CA). In this exploratory study, myocardial perfusion scintigraphy (MPS) was used to evaluate changes in the percentage of myocardial ischemia after ivabradine therapy in patients with CA. METHODS: This prospective, open-label, single-arm study included patients with CA receiving maximum tolerated doses of beta blockers, who had a resting HR ≥ 70 bpm and had experienced ischemia according to MPS during an exercise test at baseline...
March 22, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38451426/macitentan-in-pulmonary-arterial-hypertension-associated-with-connective-tissue-disease-ctd-pah-real-world-evidence-from-the-combined-opus-orpheus-dataset
#11
JOURNAL ARTICLE
Richard Channick, Kelly M Chin, Vallerie V McLaughlin, Matthew R Lammi, Roham T Zamanian, Stefano Turricchia, Rose Ong, Lada Mitchell, Nick H Kim
INTRODUCTION: Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH) are scarce. The OPUS/OrPHeUS studies enrolled patients newly initiating macitentan, including those with CTD-PAH. This analysis describes patient characteristics, treatment patterns, outcomes, and safety profiles of patients with CTD-PAH newly initiating macitentan in the US using the OPUS/OrPHeUS combined dataset. METHODS: OPUS was a prospective, US, multicenter, long-term, observational drug registry (April 2014-June 2020)...
March 7, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38381282/targeting-lipoprotein-a-can-rna-therapeutics-provide-the-next-step-in-the-prevention-of-cardiovascular-disease
#12
REVIEW
Henriette Thau, Sebastian Neuber, Maximilian Y Emmert, Timo Z Nazari-Shafti
Numerous genetic and epidemiologic studies have demonstrated an association between elevated levels of lipoprotein(a) (Lp[a]) and cardiovascular disease. As a result, lowering Lp(a) levels is widely recognized as a promising strategy for reducing the risk of new-onset coronary heart disease, stroke, and heart failure. Lp(a) consists of a low-density lipoprotein-like particle with covalently linked apolipoprotein A (apo[a]) and apolipoprotein B-100, which explains its pro-thrombotic, pro-inflammatory, and pro-atherogenic properties...
February 21, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38216822/add-on-sacubitril-valsartan-therapy-induces-left-ventricular-remodeling-in-non-responders-to-cardiac-resynchronization-therapy-to-a-similar-extent-as-in-heart-failure-patients-without-resynchronization
#13
JOURNAL ARTICLE
Krisztina Mária Szabó, Anna Tóth, László Nagy, Vivien Rácz, Zsófia Pólik, Katalin Hodosi, Attila C Nagy, Judit Barta, Attila Borbély, Zoltán Csanádi
INTRODUCTION: Non-responders to cardiac resynchronization therapy (CRT-NR) have poor prognosis. Sacubitril/valsartan (SV) treatment improved the outcome of patients with heart failure with reduced left ventricular (LV) ejection fraction (HFrEF) in randomized trials with no data on the specific cohort of CRT-NRs. The aim of this study was to compare the echocardiographic and biomarker changes in CRT-NR patients treated with versus without SV, and in patients with HFrEF on SV therapy. METHODS: CRT-NR patients initiated on SV (group I), CRT-NR patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) (group II), and patients with HFrEF (without CRT) initiated on SV (group III) were identified in our heart failure (HF) registry...
March 2024: Cardiology and Therapy
https://read.qxmd.com/read/38194058/can-artificial-intelligence-improve-the-readability-of-patient-education-materials-on-aortic-stenosis-a-pilot-study
#14
JOURNAL ARTICLE
Armaun D Rouhi, Yazid K Ghanem, Laman Yolchieva, Zena Saleh, Hansa Joshi, Matthew C Moccia, Alejandro Suarez-Pierre, Jason J Han
INTRODUCTION: The advent of generative artificial intelligence (AI) dialogue platforms and large language models (LLMs) may help facilitate ongoing efforts to improve health literacy. Additionally, recent studies have highlighted inadequate health literacy among patients with cardiac disease. The aim of the present study was to ascertain whether two freely available generative AI dialogue platforms could rewrite online aortic stenosis (AS) patient education materials (PEMs) to meet recommended reading skill levels for the public...
March 2024: Cardiology and Therapy
https://read.qxmd.com/read/38349434/the-clear-value-of-coronary-artery-calcification-evaluation-on-non-gated-chest-computed-tomography-for-cardiac-risk-stratification
#15
REVIEW
Roos A Groen, J Wouter Jukema, Paul R M van Dijkman, Jeroen J Bax, Hildo J Lamb, M Louisa Antoni, Michiel A de Graaf
To enhance risk stratification in patients suspected of coronary artery disease, the assessment of coronary artery calcium (CAC) could be incorporated, especially when CAC can be readily assessed on previously performed non-gated chest computed tomography (CT). Guidelines recommend reporting on patients' extent of CAC on these non-cardiac directed exams and various studies have shown the diagnostic and prognostic value. However, this method is still little applied, and no current consensus exists in clinical practice...
February 13, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38345713/single-pill-triple-antihypertensive-therapy-in-rural-sub-saharan-africa-preliminary-experience
#16
JOURNAL ARTICLE
Clara Stroppa, Isabella Hunjan, Alice Umulisa, Benitha Irebe, Gianfranco Parati, Mario G Bianchetti, Bienvenu Muvunyi, Evariste Ntaganda, Vincent Sinabubaraga, Dragana Radovanovic, Sebastiano A G Lava, Franco Muggli
INTRODUCTION: Worldwide, arterial hypertension is the foremost preventable and modifiable cardiovascular risk factor. In addition to lifestyle changes, recent international guidelines recommend single-pill, low-dose combinations as initial treatment strategy. We investigated whether this approach is feasible in a rural sub-Saharan Africa setting. METHODS: Diagnosis of hypertension was established over three sets of blood pressure measurements, performed according to the European Society of Hypertension recommendations by trained personnel, using a validated, automated, oscillometric device OMRON M7 IT-HEM-7322-E...
February 12, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38340292/cerebral-embolic-protection-in-transcatheter-aortic-valve-implantation-using-the-sentinel-cerebral-protection-system-a-systematic-review-and-meta-analysis
#17
JOURNAL ARTICLE
Wissam Harmouch, Barbara Karnkowska, Ravi Thakker, Peter Rasmussen, Mostafa Shalaby, Wissam Khalife, Haider Alwash, Afaq Motiwala, Paul Kumfa, Syed Gilani, Hani Jneid, Umamahesh Rangasetty
INTRODUCTION: Transcatheter aortic valve implantation (TAVI) plays a vital role in patients with symptomatic aortic stenosis. Despite the mortality benefit of TAVI, embolic stroke remains a feared complication. As a result, transcatheter cerebral embolic protection (TCEP) devices have been developed to reduce this risk. Given the ongoing debate of TCEP in TAVI, we performed a systematic review and meta-analysis of all randomized controlled trials to date to identify outcomes of periprocedural stroke using the Sentinel™ cerebral protection system (CPS)...
February 10, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38340291/contemporary-management-of-cardiomyopathy-and-heart-failure-in-pregnancy
#18
REVIEW
Henrietta Afari, Megan Sheehan, Nosheen Reza
Cardiovascular disease is the primary cause of pregnancy-related mortality and morbidity in the United States, and maternal mortality has increased over the last decade. Pregnancy and the postpartum period are associated with significant vascular, metabolic, and physiologic adaptations that can unmask new heart failure or exacerbate heart failure symptoms in women with known underlying cardiomyopathy. There are unique management considerations for heart failure in women throughout pregnancy, and it is imperative that clinicians caring for pregnant women understand these important principles...
February 10, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38326588/real-world-heart-failure-burden-in-thai-patients
#19
JOURNAL ARTICLE
Panyapat Jiampo, Thidaporn Tangkittikasem, Thanita Boonyapiphat, Vichai Senthong, Artit Torpongpun
INTRODUCTION: Heart failure (HF) is one of the leading causes of hospitalization worldwide. In Thailand, data on HF burden remains limited. This study aimed to describe comprehensive evidence detailing the HF prevalence, hospital admission rates, in-hospital mortality, and overall mortality rates at the hospital level. METHOD: All eligible adult patients' medical records from 2018 and 2019 were analyzed retrospectively at five hospitals in different regions. The patients were diagnosed with HF, as indicated by the International Classification of Diseases (ICD)-10 code I50...
February 7, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38319533/real-world-safety-and-effectiveness-of-a-4-factor-prothrombin-complex-concentrate-in-japanese-patients-experiencing-major-bleeding-a-post-marketing-surveillance-study
#20
JOURNAL ARTICLE
Masahiro Yasaka, Michiyasu Suzuki, Shigeki Kushimoto, Ayako Kiyonaga, Antoinette Mangione, Yuki Niwa, Naoki Terasaka
INTRODUCTION: Limited data are available regarding the safety and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) in patients experiencing major hemorrhage or requiring expeditious surgical intervention, both globally and within Japan. METHODS: We executed a prospective, observational post-marketing surveillance study of patients receiving 4F-PCC for the first time between September 19, 2017 and August 15, 2018 in Japan. Patients were subjected to a comprehensive follow-up for a duration of 4 weeks...
February 6, 2024: Cardiology and Therapy
journal
journal
48935
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.